...
首页> 外文期刊>New Zealand Laboratory News >Bone Therapeutics approved to produce allogeneic bone cell therapy products
【24h】

Bone Therapeutics approved to produce allogeneic bone cell therapy products

机译:骨疗法获批生产同种异体骨细胞疗法产品

获取原文
获取原文并翻译 | 示例
           

摘要

The Tissue Establishment (i.e.. Intermediate Structure) Accreditation is a pre-requisite for the manufacture of allogeneic cell therapies, and will permit Bone Therapeutics to have enhanced control over the ALLOB? production line. Bone Therapeutics' intermediate Structure will be able to process, preserve, store and distribute human tissues upon their release from LTCG, the Tissue Bank. Bone Therapeutics will work in collaboration with the LTCG, the accredited Tissue Bank from the CHU Sart-Tilman based in Liege, Belgium and headed up by Prof. Yves Beguin. This approval further strengthens Bone Therapeutics'cell product manufacturing ca-pabilities.
机译:组织认证(即中间结构)认证是制造同种异体细胞疗法的先决条件,并将使骨疗法对ALLOB有更强的控制力吗?生产线。人体组织从LTCG(组织库)中释放后,骨骼治疗剂的中间结构将能够对其进行处理,保存,储存和分配。 Bone Therapeutics将与LTCG合作,LTCG是由位于比利时列日的CHU Sart-Tilman认可的组织银行,由Yves Beguin教授领导。该批准进一步增强了骨治疗细胞产品的生产能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号